Mattiasson I, Rendell M, Törnquist C, Jeppsson S, Hulthén U L
Department of Vascular Diseases Malmö-Lund, Lund University, University Hospital, Malmö, Sweden.
Horm Metab Res. 2002 Oct;34(10):583-8. doi: 10.1055/s-2002-35420.
The effects of estrogen replacement therapy on lipid and glucose metabolism as related to abdominal fat distribution were investigated in fifty-one healthy postmenopausal women aged 52-53 years. They were randomized to treatment with either estradiol 2 mg or placebo daily for three months in a double-blind design. Forty-six women continued with estradiol for another nine months in an open design with the addition of medroxyprogesterone for ten days every three months. Intra-abdominal and subcutaneous abdominal fat, and intrapelvic and subcutaneous pelvic fat was estimated by computed tomography before and after one year of estrogen treatment. Euglycemic hyperinsulinemic clamp, oral glucose tolerance test and analyses of blood lipids were performed after 3 and 12 months of treatment. Estrogen replacement therapy decreased body fat mass as well as intra-abdominal and intrapelvic fat, but not the subcutaneous fat compartments. LDL cholesterol decreased and HDL cholesterol increased, whereas triglycerides were not changed by one year of estrogen treatment. Insulin sensitivity and glucose tolerance were not affected by estrogen treatment. In postmenopausal women estrogen treatment for one year decreased intra-abdominal and intrapelvic fat compartments, but this was not related to changes in plasma lipid levels. Insulin sensitivity and plasma triglycerides were not affected by estrogen treatment.
在51名年龄在52 - 53岁的健康绝经后女性中，研究了雌激素替代疗法对脂质和葡萄糖代谢以及与腹部脂肪分布的关系。她们被随机分为两组，采用双盲设计，一组每天服用2毫克雌二醇，另一组服用安慰剂，为期三个月。46名女性在开放设计中继续服用雌二醇另外九个月，每三个月添加甲羟孕酮服用十天。在雌激素治疗一年前后，通过计算机断层扫描估计腹部内和皮下脂肪以及盆腔内和皮下脂肪。在治疗3个月和12个月后进行正常血糖高胰岛素钳夹试验、口服葡萄糖耐量试验和血脂分析。雌激素替代疗法降低了身体脂肪量以及腹部内和盆腔内脂肪，但皮下脂肪部分未受影响。低密度脂蛋白胆固醇降低，高密度脂蛋白胆固醇升高，而雌激素治疗一年后甘油三酯未发生变化。雌激素治疗未影响胰岛素敏感性和葡萄糖耐量。在绝经后女性中，雌激素治疗一年可降低腹部内和盆腔内脂肪部分，但这与血浆脂质水平的变化无关。雌激素治疗未影响胰岛素敏感性和血浆甘油三酯。
